More on INSM
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $125.77 |
|
|||
| Open | $125.03 | ||||
| 52 Wk High | $19.30 | ||||
| 52 Wk Low | $9.02 | ||||
| Day High | $126.11 | ||||
| Day Low | $122.83 | ||||
| P/E | N/A | ||||
| EPS | $-1.69 | ||||
| Volume | 512,198 | ||||
- Japan approves Insmed's Brinsupri for lung disease treatment
- BRINSUPRI® (brensocatib) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients With Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease
- Form 4 INSMED Inc For: Aug 17 Filed by: SHAROKY MELVIN MD
- Form 144 INSMED Inc Filed by: SHAROKY MELVIN MD
- Form SCHEDULE 13G/A INSMED Inc Filed by: Darwin Global Management, Ltd.
- Form 4 INSMED Inc For: Aug 10 Filed by: Adsett Roger
- Form 144 INSMED Inc Filed by: Adsett Roger
- Insmed (INSM) PT Lowered to $175 at JPMorgan
- Insmed (INSM) PT Raised to $195 at Truist Securities
- H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)
Entities mentioned with INSM
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Definitive Agreement | View Related Stories »
- Stifel | View Related Stories »
- Show More...
